secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001641172-25-017151
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)
--------------------------------------------------------------------------------

- Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.
- Operating profit rose 81% to $19.6M, driven by lisdexamfetamine products launched in FY2025 and Elite label product lines.
- Conference call scheduled for July 1, 2025 at 11:30 AM EDT to discuss results and business update.
- Company requests stockholder questions be submitted by 7:00 PM EDT on June 30, 2025.
- No EPS or net income figures disclosed in the press release; full 10-K filed separately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/0001641172-25-017151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer